CNMD vs. MASI, TMDX, ITGR, LIVN, INMD, SLNO, BLFS, ZYXI, AXGN, and SMLR
Should you be buying CONMED stock or one of its competitors? The main competitors of CONMED include Masimo (MASI), TransMedics Group (TMDX), Integer (ITGR), LivaNova (LIVN), InMode (INMD), Soleno Therapeutics (SLNO), BioLife Solutions (BLFS), Zynex (ZYXI), AxoGen (AXGN), and Semler Scientific (SMLR). These companies are all part of the "electromedical equipment" industry.
Masimo (NASDAQ:MASI) and CONMED (NYSE:CNMD) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, community ranking, analyst recommendations, risk, dividends, media sentiment and valuation.
Masimo received 427 more outperform votes than CONMED when rated by MarketBeat users. Likewise, 63.84% of users gave Masimo an outperform vote while only 42.37% of users gave CONMED an outperform vote.
86.0% of Masimo shares are owned by institutional investors. 9.7% of Masimo shares are owned by insiders. Comparatively, 6.8% of CONMED shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Masimo has a beta of 0.99, indicating that its share price is 1% less volatile than the S&P 500. Comparatively, CONMED has a beta of 1.37, indicating that its share price is 37% more volatile than the S&P 500.
CONMED has a net margin of 6.53% compared to CONMED's net margin of 4.01%. Masimo's return on equity of 13.78% beat CONMED's return on equity.
Masimo has higher revenue and earnings than CONMED. CONMED is trading at a lower price-to-earnings ratio than Masimo, indicating that it is currently the more affordable of the two stocks.
In the previous week, Masimo had 16 more articles in the media than CONMED. MarketBeat recorded 18 mentions for Masimo and 2 mentions for CONMED. CONMED's average media sentiment score of 0.46 beat Masimo's score of 0.40 indicating that Masimo is being referred to more favorably in the media.
Masimo presently has a consensus price target of $138.71, suggesting a potential upside of 11.42%. CONMED has a consensus price target of $102.50, suggesting a potential upside of 34.09%. Given Masimo's stronger consensus rating and higher possible upside, analysts clearly believe CONMED is more favorable than Masimo.
Summary
Masimo beats CONMED on 11 of the 18 factors compared between the two stocks.
Get CONMED News Delivered to You Automatically
Sign up to receive the latest news and ratings for CNMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CNMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
